Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Total Current Liabilities
All obligations due within one year.
Immix Biopharma, Inc.NASDAQ: IMMX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 13.2% from a year ago
Total current liabilities stood at $10.54M at the end of Q1 FY2026, up 13.2% from a year earlier and up 4.2% from the prior quarter. Over 3 fiscal years it compounded at +99.5% a year.
Context
- Total current liabilities amounted to 11.0% of total assets at the end of Q1 FY2026, down 35.8 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +13.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.11M USD
- Year-over-year change
- +16.4%
- 4-year CAGR
- +166.0%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.11M | +16.4% |
| FY2024 | 2024-12-31 | 8.69M | +133.4% |
| FY2023 | 2023-12-31 | 3.72M | +192.3% |
| FY2022 | 2022-12-31 | 1.27M | +530.2% |
| FY2021 | 2021-12-31 | 202.04K | — |
Total Current Liabilities vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +13.2% is the 6th highest of 11, against a peer median of +19.5%.
- Total current liabilities amounts to 11.0% of total assets for IMMX, versus a peer median of 17.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $198M USD | -5.7% | +6.2% | 21.4% | |
| Aug 2026 | $130.74M USD | +58.8% | +7.0% | 10.9% | |
| Mar 2026 | $95.94M USD | +73.0% | -3.9% | 44.0% | |
| Jun 2026 | €71.69M EUR | -36.2% | +7.0% | 15.5% | |
| Sep 2026 | $60.52M USD | +30.2% | +39.9% | 8.4% | |
| Dec 2025 | A$47.01M AUD | +410.3% | +25.8% | 31.9% | |
| Mar 2026 | $38.36M USD | +49.9% | +32.8% | 20.2% | |
| Mar 2026 | $34.02M USD | -32.2% | -32.7% | 9.5% | |
| Mar 2026 | $14.46M USD | +8.8% | +28.1% | 29.4% | |
| Mar 2026 | $10.54M USD | +13.2% | +99.5% | 11.0% | |
NBPNovaBridge Biosciences | Dec 2025 | $3.84M USD | -93.8% | -82.0% | 10.3% |
| Peer median (excluding IMMX) | — | +19.5% | +7.0% | 17.9% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17.64M | 13.44M | 17.51M | 17.68M | 93.93M |
| Short-term Investments | 0 | 0 | 0 | 0 | 6.48M |
| Net Receivables | 25.72K | 255.71K | 1.17M | 1.97M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 516.19K | 78.07K | 44.58K | 32.27K | 150.72K |
| Total Current Assets | 18.19M | 14.9M | 19.79M | 20.2M | 101.24M |
| Property, Plant & Equipment (Net) | 5.7K | 3.56K | 50.18K | 2.73M | 3.49M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (0) | 6.72K | 87.23K | 20.42K | 114.05K |
| Total Non-current Assets | 5.7K | 10.28K | 137.41K | 2.75M | 3.6M |
| Total Assets | 18.19M | 14.91M | 19.93M | 22.95M | 104.84M |
| Account Payables | 142.94K | 143.07K | 1.43M | 5.39M | 5.44M |
| Short-term Debt | 50K | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 658.16K | 0 |
| Total Current Liabilities | 202.04K | 1.27M | 3.72M | 8.69M | 10.11M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 475K | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 475K | 0 | 1.01M | 933.63K |
| Total Liabilities | 202.04K | 1.75M | 3.72M | 9.7M | 11.04M |
| Common Stock | 1.32K | 1.4K | 2K | 2.76K | 5.3K |
| Retained Earnings | (29.76M) | (37.99M) | (53.41M) | (75.02M) | (104.46M) |
| Accumulated OCI | 125.41K | 87.02K | 134.67K | (1.06K) | 60.16K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | (201.74K) | 0 | 0 |
| Total Equity | 17.99M | 13.16M | 16.2M | 13.25M | 93.8M |
| Total Debt | 50K | 0 | 0 | 1.07M | 1.07M |
| Net Debt | (17.59M) | (13.44M) | (17.51M) | (16.61M) | (92.86M) |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.